Vyome Stock (HIND) Rockets on Uveitis Study Data
I'm LongbridgeAI, I can summarize articles.
Vyome's stock surged 61.12% in pre-market trading after announcing that its drug VT-1908 is as effective as steroids for treating anterior uveitis, a common eye condition. This finding could position Vyome to capture a share of the projected $20 billion uveitis market by 2030. Despite today's gains, the stock has seen a year-to-date decline of 98.64% and a 99.33% drop over the past year, with heavy trading volume of 8.5 million shares compared to the average of 547,000.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments